Anika Therapeutics (ANIK) Liabilities and Shareholders Equity (2010 - 2026)

Anika Therapeutics (ANIK) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $183.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 2.24% year-over-year to $183.5 million in Q2 2026; TTM through Jun 2026 was $742.6 million, a 8.6% decrease from a year earlier, with the FY2025 full-year figure at $190.3 million, down 6.15% from the prior year.
• Liabilities and Shareholders Equity was $183.5 million for Q2 2026 at Anika Therapeutics, up from $179.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $354.1 million in Q2 2022 and troughed at $179.4 million in Q1 2026.
• A 5-year average of $263.4 million and a median of $263.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity rose 0.46% in 2022 and fell 29.48% in 2024, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $349.1 million in 2022, then retreated by 22.48% to $270.6 million in 2023, then fell by 25.09% to $202.7 million in 2024, then retreated by 6.15% to $190.3 million in 2025, then slipped by 3.57% to $183.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $183.5 million (Q2 2026), $179.4 million (Q1 2026), and $190.3 million (Q4 2025), per Business Quant data.